Xospata's progress in expanding insurance benefits, which seemed to be going smoothly, appears to have stopped.

According to related industries, Astellas Korea Pharmaceutical's FLT3 mutation-positive recurrence or Acute Myeloid Leukemia treatment Xospata was not submitted during the three HIRA Pharmaceutical Reimbursement Evaluation Committee meetings held from July to September.

Expectations were high when an application for benefit expansion was submitted in February and passed the Cancer Disease Review Committee in May, but it is believed that differences of opinion regarding finances arose during the subsequent procedures.

As Xospata is a PE-exempt drug, the NHIS drug